{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:09:46Z","timestamp":1761419386343,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001504","name":"Ministry of Health, New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001504","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008810","name":"NSW Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.hlc.2020.03.013","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T07:51:27Z","timestamp":1586764287000},"page":"1386-1396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34)"],"prefix":"10.1016","volume":"29","author":[{"given":"Daniel","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N.","family":"Doughty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayanna","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mildred","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hlc.2020.03.013_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/01.CIR.0000109691.16944.DA","article-title":"Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE)","volume":"109","author":"Steg","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2020.03.013_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2016.05.003","article-title":"The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database","volume":"178","author":"Sutton","year":"2016","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.hlc.2020.03.013_bib3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.hlc.2015.10.007","article-title":"Management and long-term outcome of acute coronary syndrome patients presenting with heart failure in a contemporary New Zealand cohort (ANZACS-QI 4)","volume":"25","author":"Kueh","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"2","key":"10.1016\/j.hlc.2020.03.013_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hlc.2020.03.013_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.hlc.2020.03.013_bib6","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.jacc.2009.10.005","volume":"54","author":"Murphy","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hlc.2020.03.013_bib7","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.hlc.2020.03.013_bib8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jama.2012.452","article-title":"Association of treatment with losartan vs candesartan and mortality among patients with heart failure","volume":"307","author":"Svanstrom","year":"2012","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.hlc.2020.03.013_bib9","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.hlc.2020.03.013_bib10","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"MOCHA Investigators. Circulation"},{"issue":"3","key":"10.1016\/j.hlc.2020.03.013_bib11","doi-asserted-by":"crossref","first-page":"454.e1","DOI":"10.1016\/j.ahj.2006.02.030","article-title":"National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance","volume":"152","author":"Kramer","year":"2006","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.hlc.2020.03.013_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/CIRCULATIONAHA.105.505636","article-title":"Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease","volume":"113","author":"Newby","year":"2006","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.hlc.2020.03.013_bib13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","article-title":"Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction","volume":"62","author":"Arnold","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2020.03.013_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1439","key":"10.1016\/j.hlc.2020.03.013_bib15","first-page":"23","article-title":"The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9)","volume":"129","author":"Kerr","year":"2016","journal-title":"NZ Med J"},{"issue":"1492","key":"10.1016\/j.hlc.2020.03.013_bib16","first-page":"19","article-title":"High level of capture of coronary intervention and associated acute coronary syndromes in the all New Zealand acute coronary syndrome quality improvement cardiac registry and excellent agreement with national administrative datasets (ANZACS-QI 25)","volume":"132","author":"Kerr","year":"2019","journal-title":"NZ Med J"},{"issue":"16","key":"10.1016\/j.hlc.2020.03.013_bib17","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hlc.2020.03.013_bib18","first-page":"e148","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.hlc.2020.03.013_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.hlc.2020.03.013_bib20","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.hlc.2020.03.013_bib21","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"25 Suppl 2","key":"10.1016\/j.hlc.2020.03.013_bib22","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"1400","key":"10.1016\/j.hlc.2020.03.013_bib23","first-page":"39","article-title":"Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1)","volume":"127","author":"Kerr","year":"2014","journal-title":"NZ Med J"},{"issue":"9266","key":"10.1016\/j.hlc.2020.03.013_bib24","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.hlc.2020.03.013_bib25","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hlc.2020.03.013_bib26","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2020.03.013_bib27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.hlc.2020.03.013_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hlc.2020.03.013_bib29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/heartjnl-2014-306754","article-title":"Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction","volume":"101","author":"Shore","year":"2015","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.hlc.2020.03.013_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/archinternmed.2008.563","article-title":"Understanding physicians' risk stratification of acute coronary syndromes: insights from the Canadian ACS 2 Registry","volume":"169","author":"Yan","year":"2009","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.hlc.2020.03.013_bib31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archinte.167.10.1019","article-title":"Exploring the treatment-risk paradox in coronary disease","volume":"167","author":"McAlister","year":"2007","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.hlc.2020.03.013_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamacardio.2016.0001","article-title":"Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction","volume":"1","author":"Faridi","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.hlc.2020.03.013_bib33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamacardio.2016.2332","article-title":"Nurse-led titration of angiotensin-converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers in patients with heart failure with reduced ejection fraction","volume":"1","author":"Driscoll","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"9535","key":"10.1016\/j.hlc.2020.03.013_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.hlc.2020.03.013_bib35","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hlc.2020.03.013_bib36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hlc.2020.03.013_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062030113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062030113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:01:54Z","timestamp":1761415314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S144395062030113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S144395062030113X"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2020.03.013","relation":{},"ISSN":["1443-9506"],"issn-type":[{"type":"print","value":"1443-9506"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34)","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2020.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}